PMC8247584_01
Functional imaging of right and left paraganglioma and response to sunitinib treatment assesed by PERCIST criteria. (A) 18F-fluoro-dihydroxyphenylalanine (18F-DOPA) positron emission tomography (PET)-computed tomography (CT) in May 2018; (B) 68Ga-DOTA-D-Phe1-Tyr3-Octreotate (68Ga-DOTATOC) PET-CT in October 2018; (C) 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)-computed tomography (CT) with contrast medium performed after the third cycle of therapy in June 2020; (D) peak standardized uptake value corrected for lean body mass (SULpeak) trend for the hottest lesion between the two susequent 18F-FDG PET-CT (October 2020 and June 2020).
fonc-11-677983-g001.jpg
PMC8247584_01_fonc-11-677983-g001.jpg
f1
Both lesions showed significant uptake of radiotracer at 18F-fluoro-dihydroxyphenylalanine (18F-DOPA) positron emission tomography (PET)-CT with a SUVmax of 10.5 on the left and 5.66 on the right, and at 68Ga-DOTA-D-Phe1-Tyr3-Octreotate (68Ga-DOTATOC) PET-CT ( Figures 1A, B ). The peak standardized uptake value corrected for lean body mass (SULpeak) of the left lesion was reduced by 18% ( Figures 1C, D ).
Response to sunitinib treatment assesed by magnetic resonance (MR). (A) coronal contrast-enhanced MR scan (fat-sat T1 sequence) of left paraganglioma in April 2019; (B) coronal contrast-enhanced MR scan (fat-sat T1 sequence) of left paraganglioma in July 2020; (C) coronal contrast-enhanced MR scan (fat-sat T1 sequence) of left paraganglioma in March 2021; (D) axial contrast-enhanced MR scan (T2 sequence) of left paraganglioma in April 2019; (E) axial contrast-enhanced MR scan (T2 sequence) of left paraganglioma in July 2020; (F) axial contrast-enhanced MR scan (T2 sequence) of left paraganglioma in March 2021.
fonc-11-677983-g002.jpg
PMC8247584_01_fonc-11-677983-g002.jpg
f2
Thus, under sunitinib treatment the patient has been stable for 17 months ( Figure 2 ).